Spotlight -

AMCP Nexus 2026|

State of the Industry survey: Share your 2027 outlook|

Biologics

Latest News

Latest Videos

Impact of an "Open" Market on Biosimilar Development

Impact of an "Open" Market on Biosimilar Development

Evidence-Based Recommendations and Safety Considerations Surrounding Biosimilars

Evidence-Based Recommendations and Safety Considerations Surrounding Biosimilars

Overview of Originator Biologics, Biosimilars, and Unbranded Biologics

Overview of Originator Biologics, Biosimilars, and Unbranded Biologics

Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars

Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars

Implications of Multiple Switching with Biologic Therapies

Implications of Multiple Switching with Biologic Therapies

Differentiating Between Unbranded Biologics and Biosimilars

Differentiating Between Unbranded Biologics and Biosimilars

Emphasizing Biologics Space as Payer Priority

Emphasizing Biologics Space as Payer Priority

Clinical Impacts of Biologics on Patient Quality of Care

Clinical Impacts of Biologics on Patient Quality of Care

Overview and Prevalence of Biologics

Overview and Prevalence of Biologics

CME Content

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Florida Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Florida Regional Program

Frantz Francisque, MD; Jacob Sands, MD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Michigan Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Michigan Regional Program

Jacob Sands, MD; Shiven B. Patel, MD, MBA, FACP

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Alabama Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Alabama Regional Program

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Illinois Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Illinois Regional Program

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Tennessee Oncology Practice Society

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Tennessee Oncology Practice Society

Jack W. Erter III, MD, MMHC; Anne Chiang, MD, PhD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Indiana Oncology Society

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Indiana Oncology Society

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Wisconsin Association of Hematology and Oncology

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Wisconsin Association of Hematology and Oncology

Neel Belani, MD; Eric K. Singhi, MD

Arizona Clinical Oncology Society

Arizona Clinical Oncology Society

1 Session is Available!

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable, Early-Stage NSCLC

Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable, Early-Stage NSCLC

Mara Antonoff, MD, FACS; Laura Alder, MD; Stephanie Worrell, MD, FACS

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Narjust Florez, MD, FASCO; David P. Carbone, MD, PhD; Edward B. Garon, MD, MS

Live Tumor Board: From Trial to Practice–Integrating the Latest Evidence Into the Treatment of EGFR-Mutated NSCLC

Live Tumor Board: From Trial to Practice–Integrating the Latest Evidence Into the Treatment of EGFR-Mutated NSCLC

Jonathan Riess, MD, MS; Fawzi Abu Rous, MD; Julia Rotow, MD

Burst CME Expert Illustrations & Commentaries™: Breaking Down DLL3-Targeting Immune Cell Effector Agents in SCLC

Burst CME Expert Illustrations & Commentaries™: Breaking Down DLL3-Targeting Immune Cell Effector Agents in SCLC

Jacob Sands, MD; Anne Chiang, MD, PhD

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, MBS

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

More News

Image credit: © lexiconimage stock.adobe.com

FDA Approves Simlandi, Third Interchangeable Humira Biosimilar

ByPeter Wehrwein, Managing Editor

February 24th 2024

At the moment, Simlandi (adalimumab-ryvk) has the high-concentration, citrate-free, interchangeable Humira (adalimumab) market to itself.

2024 Formulary Moves

ByDenise Myshko

January 5th 2024

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).

Biosimilars are Ascendant

ByTony Hagen,Peter Wehrwein, Managing Editor

December 19th 2023

Acceptance is greater in oncology than in other specialties.

Biosimilar K-Cast - "Overcoming Challenges Associated with Biosimilars"

Overcoming Challenges Associated with Biosimilars

October 11th 2023

Challenges with biosimilars and unbranded biologics are discussed and how can they be improved.

Trending on Managed Healthcare Executive

WHO adds two Bundibugyo vaccines to Ebola trial in the DRC

On Medicaid cuts, the Medicare Advantage market, commercial insurance and the future of U.S. health insurance: A conversation with Geisinger's Jeremy Gaskill

Cigna’s third-quarter earnings show a drop in income from its pharmacy benefit business

Medicare changes are here to stay. 3 ways health plans can support members through them

8 takeaways from the MHE and Drug Topics post-midterms webinar